EFFECT OF TUMOR BURDEN AND ROUTE OF ADMINISTRATION ON THE IMMUNOTHERAPEUTIC PROPERTIES OF POLYINOSINIC POLYCYTIDYLIC ACID STABILIZED WITH POLY-L-LYSINE IN CARBOXYMETHYL CELLULOSE [POLY(I,C)-LC]

被引:11
作者
BLACK, PL
HARTMANN, D
PENNINGTON, R
PHILLIPS, H
SCHNEIDER, M
TRIBBLE, HR
TALMADGE, JE
机构
[1] NIPPON LAROCHE,KANAGAWA 247,JAPAN
[2] NIH,FREDERICK CANC RES,PRECLIN SCREENING LAB,FREDERICK,MD 21702
[3] SMITHKLINE BEECHAM PHARMACEUT,KING OF PRUSSIA,PA 19406
[4] UNIV NEBRASKA,MED CTR,OMAHA,NE 68198
来源
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY | 1992年 / 14卷 / 08期
关键词
D O I
10.1016/0192-0561(92)90005-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We examined the immunomodulatory and therapeutic activities of poly(I,C) - LC. Mice received a subcutaneous (s.c.) injection of sufficient numbers of MBL-2 lymphoma cells to produce in 1 week either a high or low tumor burden. A week after tumor cell injection, poly(I,C) - LC treatment was initiated; the agent was administered intraperitoneally (i.p.) at 5 mg/kg twice a week or at 2.5 or 0.5 mg/kg every day or as an intravenous (i.v.) injection at 0.5, 0.05, or 0.005 mg/kg three times a week. Poly(I,C) - LC treatment significantly increased antitumor effector cell functions in a variety of organs (including spleen, lungs, and peritoneum), as shown by increased killing of MBL-2 cells in vitro and increased tumor cell killing by natural killer cells and macrophages. Furthermore, prolongation of survival correlated with peritoneal macrophage tumoricidal activity when poly(I,C) - LC was given i.p. and with pulmonary effector cell function (including natural killer, cytolytic T-lymphocyte and macrophage tumoricidal activity) when the agent was administered i.v.
引用
收藏
页码:1341 / 1353
页数:13
相关论文
共 59 条
  • [1] BEERS R F JR, 1971, P344
  • [2] BUCKLER CE, 1971, P SOC EXP BIOL MED, V136, P394
  • [3] CANTOR H, 1970, J IMMUNOL, V104, P1035
  • [4] CATALANO LW, 1970, P SOC EXP BIOL MED, V133, P684, DOI 10.3181/00379727-133-34544
  • [5] MODIFIED POLYRIBOINOSINIC-POLYRIBOCYTIDYLIC ACID COMPLEX - SUSTAINED INTERFERONEMIA AND ITS PHYSIOLOGICAL ASSOCIATES IN HUMANS
    CHAMPNEY, KJ
    LEVINE, DP
    LEVY, HB
    LERNER, AM
    [J]. INFECTION AND IMMUNITY, 1979, 25 (03) : 831 - 837
  • [6] IMMUNE-RESPONSE MODIFYING ACTIVITY IN MICE OF POLYINOSINIC - POLYCYTIDYLIC ACID STABILIZED WITH POLY-L-LYSINE, IN CARBOXYMETHYLCELLULOSE [POLY-ICLC]
    CHIRIGOS, MA
    PAPADEMETRIOU, V
    BARTOCCI, A
    READ, E
    LEVY, HB
    [J]. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1981, 3 (04): : 329 - 337
  • [7] CHIRIGOS MA, 1982, ADV IMMUNOPHARMACOL, V2, P669
  • [8] COHEN SA, 1990, CANCER RES, V50, P1834
  • [9] EFFECT OF POLY-I-C-POLY-L-LYSINE (POLY ICL) ON THE DEVELOPMENT OF MURINE OSTEOGENIC-SARCOMA
    DAVIES, ME
    FIELD, AK
    [J]. JOURNAL OF INTERFERON RESEARCH, 1983, 3 (01): : 89 - 95
  • [10] DJEU JY, 1979, J IMMUNOL, V122, P182